Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BOEHRINGER INGELHEIM's ATROVENT NASAL SPRAY FOR RHINORRHEA

Executive Summary

BOEHRINGER INGELHEIM's ATROVENT NASAL SPRAY FOR RHINORRHEA associated with perennial rhinitis and the common cold was recommended for approval by FDA's Pulmonary-Allergy Drugs Advisory Committee on July 15 despite questions regarding the degree of clinical effect of the anticholinergic agent in the sponsor's studies. The committee voted 6-2 in favor of approving the new formulation of ipratropium bromide for rhinorrhea associated with perennial allergic rhinitis and unanimously for perennial non- allergic rhinitis and the common cold.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS024773

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel